regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophagogastric Cancer
Conditions
Esophagogastric Cancer, HER2-Negative
Trial Timeline
Feb 11, 2021 → Feb 1, 2027
NCT ID
NCT04757363About regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin
regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin is a phase 2 stage product being developed by Bristol Myers Squibb for Esophagogastric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04757363. Target conditions include Esophagogastric Cancer, HER2-Negative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04757363 | Phase 2 | Active |
Competing Products
6 competing products in Esophagogastric Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO | Daiichi Sankyo | Phase 1/2 | 41 |
| Pembrolizumab + Trastuzumab + FLOT | Merck | Phase 2 | 52 |
| bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib | Roche | Phase 2/3 | 65 |
| Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo | Amgen | Phase 1/2 | 40 |
| Sacituzumab govitecan | Gilead Sciences | Phase 1/2 | 40 |
| 18F-BMS-986229 Injection + IV 18F-BMS-986229 | Bristol Myers Squibb | Pre-clinical | 22 |